ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
Saved in:
| Title: | ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). |
|---|---|
| Authors: | Ferrando L; IRCCS Ospedale Policlinico San Martino, Genova, Italy., Vingiani A; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Garuti A; IRCCS Ospedale Policlinico San Martino, Genova, Italy., Vernieri C; Department of Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; IFOM, The FIRC Institute of Molecular Oncology, Milan, Italy., Belfiore A; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Agnelli L; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Dagrada G; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ivanoiu D; Department of Surgery and Cancer, Imperial College London, London, United Kingdom., Bonizzi G; Department of Pathology, IEO European Institute of Oncology IRCCS, Milan, Italy., Munzone E; Division of Medical Senology, IEO European Institute of Oncology IRCCS, Milan, Italy., Lippolis L; Division of Pathology, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy., Dameri M; Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy., Ravera F; Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy., Colleoni M; Division of Medical Senology, IEO European Institute of Oncology IRCCS, Milan, Italy., Viale G; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Department of Pathology, IEO European Institute of Oncology IRCCS, Milan, Italy., Magnani L; Department of Surgery and Cancer, Imperial College London, London, United Kingdom., Ballestrero A; IRCCS Ospedale Policlinico San Martino, Genova, Italy.; Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy., Zoppoli G; IRCCS Ospedale Policlinico San Martino, Genova, Italy.; Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy., Pruneri G; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. |
| Source: | PLoS genetics [PLoS Genet] 2023 Jan 03; Vol. 19 (1), pp. e1010563. Date of Electronic Publication: 2023 Jan 03 (Print Publication: 2023). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101239074 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7404 (Electronic) Linking ISSN: 15537390 NLM ISO Abbreviation: PLoS Genet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1553-7404 |
|---|---|
| DOI: | 10.1371/journal.pgen.1010563 |
